Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Arteris, Inc.'s SEC filings can feel like navigating a dense wiring diagram—hundreds of pages on deferred royalties, automotive safety certifications, and stock-based compensation. If you need the revenue backlog buried in a 10-K or want to spot Form 4 trades before the next design-win press release, the traditional EDGAR search simply takes too long.
Stock Titan solves this problem. Our AI-powered summaries translate complex semiconductor accounting into plain language, flagging key metrics such as licensing revenue mix, R&D capitalization trends, and customer concentration. Real-time alerts pull every Arteris quarterly earnings report 10-Q filing, 8-K material events explained in minutes, and Arteris insider trading Form 4 transactions as they post—so you never miss a disclosure.
Here’s what you can uncover instantly:
- Arteris annual report 10-K simplified—royalty schedules, risk factors, and segment performance distilled within seconds.
- Arteris Form 4 insider transactions real-time—track executive stock sales or option exercises alongside AI context on upcoming product milestones.
- Proxy statement executive compensation—see how design-win milestones affect equity awards without combing through tables.
- Arteris earnings report filing analysis—compare quarter-over-quarter gross margin shifts and R&D intensity.
Whether you’re monitoring executive stock transactions, assessing patent litigation exposure, or just trying to understand Arteris SEC filings explained simply, our platform surfaces the data professionals rely on—no jargon, no delays.
Arteris, Inc. (AIP) Form 4 filing: Chief Operating Officer Laurent R. Moll sold 294 shares of common stock on 1 Jul 2025 through a pre-arranged Rule 10b5-1 trading plan adopted 12 Mar 2025. The weighted-average sale price was $9.0869 per share, with transactions executed between $8.81 and $9.32. After the sale, Moll directly owns 483,465 shares of Arteris common stock. No derivative security activity was reported.
The transaction represents less than 0.1 % of Moll’s reported holdings and does not appear material to the company’s capital structure.
Arteris, Inc. (AIP) – Form 4 Insider Transaction
Director S. Atiq Raza, acting through the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust, sold 19,809 shares of Arteris common stock on 27 June 2025 under a pre-arranged Rule 10b5-1 trading plan adopted on 6 June 2024. The weighted-average sale price was $10.02 per share (individual trade prices ranged from $10.00 to $10.10).
Following the transaction, the trust continues to hold 683,798 shares, leaving Mr. Raza with a substantial ownership position. The filing states that the trade was reported on 1 July 2025 and was executed indirectly through the trust.
- Form type: SEC Form 4
- Insider role: Director
- Nature of trade: Open-market sale (code “S”)
- Approximate transaction value: $199,000
The relatively small percentage of shares sold (≈2.8 % of the insider’s reported holdings) and the existence of a 10b5-1 plan mitigate potential negative signalling, yet investors often monitor insider sales for sentiment clues.